Takeda Pharmaceutical Co Stock

Takeda Pharmaceutical Co Net Income 2024

Takeda Pharmaceutical Co Net Income

144.07 B JPY

Ticker

4502.T

ISIN

JP3463000004

WKN

853849

In 2024, Takeda Pharmaceutical Co's profit amounted to 144.07 B JPY, a -54.56% increase from the 317.02 B JPY profit recorded in the previous year.

The Takeda Pharmaceutical Co Net Income history

YEARNET INCOME (undefined JPY)
2027e298.56
2026e224.73
2025e123.61
2024144.07
2023317.02
2022230.06
2021376.01
202044.24
2019135.19
2018186.89
2017114.94
201680.17
2015-145.78
2014106.66
2013131.24
2012124.16
2011247.87
2010297.74
2009234.39
2008355.45
2007335.81
2006312.9
2005277.09

Takeda Pharmaceutical Co Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

Understanding Revenue, EBIT, and Income

Gain insights into Takeda Pharmaceutical Co, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Takeda Pharmaceutical Co from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Takeda Pharmaceutical Co’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Takeda Pharmaceutical Co. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Takeda Pharmaceutical Co’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Takeda Pharmaceutical Co’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Takeda Pharmaceutical Co’s growth potential.

Takeda Pharmaceutical Co Revenue, EBIT and net profit per share

DateTakeda Pharmaceutical Co RevenueTakeda Pharmaceutical Co EBITTakeda Pharmaceutical Co Net Income
2027e4.56 T undefined503.99 B undefined298.56 B undefined
2026e4.5 T undefined401.98 B undefined224.73 B undefined
2025e4.45 T undefined228.26 B undefined123.61 B undefined
20244.26 T undefined430.79 B undefined144.07 B undefined
20234.03 T undefined550.9 B undefined317.02 B undefined
20223.57 T undefined545.49 B undefined230.06 B undefined
20213.2 T undefined335.72 B undefined376.01 B undefined
20203.29 T undefined286.5 B undefined44.24 B undefined
20192.1 T undefined183.49 B undefined135.19 B undefined
20181.77 T undefined202.84 B undefined186.89 B undefined
20171.73 T undefined191.25 B undefined114.94 B undefined
20161.81 T undefined147.16 B undefined80.17 B undefined
20151.78 T undefined88.69 B undefined-145.78 B undefined
20141.69 T undefined151.73 B undefined106.66 B undefined
20131.56 T undefined122.51 B undefined131.24 B undefined
20121.51 T undefined265.03 B undefined124.16 B undefined
20111.42 T undefined367.08 B undefined247.87 B undefined
20101.47 T undefined420.21 B undefined297.74 B undefined
20091.54 T undefined306.47 B undefined234.39 B undefined
20081.37 T undefined423.12 B undefined355.45 B undefined
20071.31 T undefined458.5 B undefined335.81 B undefined
20061.21 T undefined402.81 B undefined312.9 B undefined
20051.12 T undefined381.03 B undefined277.09 B undefined

Takeda Pharmaceutical Co stock margins

The Takeda Pharmaceutical Co margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Takeda Pharmaceutical Co. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Takeda Pharmaceutical Co.
  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Takeda Pharmaceutical Co's sales revenue. A higher gross margin percentage indicates that the Takeda Pharmaceutical Co retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Takeda Pharmaceutical Co's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Takeda Pharmaceutical Co's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Takeda Pharmaceutical Co's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Takeda Pharmaceutical Co. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Takeda Pharmaceutical Co's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Takeda Pharmaceutical Co Margin History

Takeda Pharmaceutical Co Gross marginTakeda Pharmaceutical Co Profit marginTakeda Pharmaceutical Co EBIT marginTakeda Pharmaceutical Co Profit margin
2027e66.54 %11.04 %6.54 %
2026e66.54 %8.93 %4.99 %
2025e66.54 %5.13 %2.78 %
202466.54 %10.1 %3.38 %
202369.11 %13.68 %7.87 %
202268.99 %15.28 %6.45 %
202168.91 %10.5 %11.76 %
202066.89 %8.71 %1.34 %
201968.92 %8.75 %6.45 %
201871.99 %11.46 %10.56 %
201767.74 %11.04 %6.64 %
201670.38 %8.14 %4.44 %
201570.7 %4.99 %-8.2 %
201471.02 %8.97 %6.3 %
201371.26 %7.87 %8.43 %
201271.29 %17.56 %8.23 %
201177.63 %25.86 %17.46 %
201080.55 %28.66 %20.31 %
200981.18 %19.92 %15.24 %
200879.73 %30.78 %25.85 %
200778.57 %35.13 %25.73 %
200676.73 %33.23 %25.81 %
200575.14 %33.93 %24.67 %

Takeda Pharmaceutical Co Aktienanalyse

What does Takeda Pharmaceutical Co do?

Takeda Pharmaceutical Co Ltd is a Japanese company that operates in the pharmaceutical industry. The company was founded in 1781 by Chobei Takeda as a traditional pharmacy specializing in herbal medicine. Nowadays, the company is a leading player in the global pharmaceutical industry. Business model: Takeda aims to help people worldwide through the development of groundbreaking therapies and drugs. The company has a strong research and development department that focuses on the discovery of new therapies and the improvement of existing medications. Takeda has made global partnerships and acquisitions to leverage the combination of science and technology and ensure better patient care. Divisions: Takeda operates in four main divisions: Gastrointestinal (GI), Oncology, Rare Diseases, and Neuroscience. In the GI division, the company is a global leader in the treatment of gastrointestinal diseases such as Crohn's disease and ulcerative colitis. The Oncology division aims to develop novel cancer therapies and provide patients with a higher quality of life. The Rare Diseases division specializes in the development of medications for rare diseases. The Neuroscience division focuses on developing medications to combat nervous system disorders such as Alzheimer's and Parkinson's. Products: Takeda's product range includes a variety of medications used worldwide to treat various diseases. One example is enzyme replacement therapy, which is administered to patients with a rare disease. Another example is Entyvio, a medication used to treat Crohn's disease and ulcerative colitis. Takeda also has medications in the Oncology division, such as Adcetris, a therapeutic agent against certain lymphomas and leukemia. In summary, Takeda Pharmaceutical Co Ltd is a leading company in the global pharmaceutical industry. The company's business model is based on the development of groundbreaking therapies and medications to improve patient care. With a focus on the GI, Oncology, Rare Diseases, and Neuroscience divisions, Takeda offers a variety of products for the treatment of various diseases. Takeda Pharmaceutical Co ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Net Income Details

Understanding Takeda Pharmaceutical Co's Profit Margins

The profit margins of Takeda Pharmaceutical Co represent the net income earned after deducting all operational expenses, costs, and taxes from the revenue. This figure is a clear indicator of Takeda Pharmaceutical Co's financial health, operational efficiency, and profitability. Higher profit margins signify better cost management and income generation capabilities.

Year-to-Year Comparison

Evaluating Takeda Pharmaceutical Co's profit on a yearly basis can offer significant insights into its financial growth, stability, and trends. A consistent increase in profit suggests improved operational efficiency, cost management, or increased revenue, while a decrease may indicate rising costs, declining sales, or operational challenges.

Impact on Investments

Takeda Pharmaceutical Co's profit figures are critical for investors who are aiming to understand the company's financial standing and future growth prospects. Increased profits often lead to higher stock valuations, boosting investor confidence and attracting more investments.

Interpreting Profit Fluctuations

When Takeda Pharmaceutical Co’s profit increases, it often indicates enhanced operational efficiency or increased sales. In contrast, a decline in profit can signal operational inefficiencies, increased costs, or competitive pressures, necessitating strategic interventions to boost profitability.

Frequently Asked Questions about Takeda Pharmaceutical Co stock

How much profit has Takeda Pharmaceutical Co made this year?

Takeda Pharmaceutical Co has made 144.07 B JPY this year.

How has the profit developed compared to last year?

The profit has increased by -54.56% compared to last year fallen

What impact do the earnings have on the shareholders?

An increase in earnings is usually seen as a positive indicator for shareholders as it means that the company is generating profits.

How does Takeda Pharmaceutical Co publish its earnings?

Takeda Pharmaceutical Co publishes its earnings in the form of quarterly or annual reports.

Which financial indicators are included in the quarterly or annual reports?

The quarterly or annual reports contain information about sales and profit, cash flow, balance sheet, and other fundamentals.

Why is it important for investors to know the earnings of Takeda Pharmaceutical Co?

The profits of Takeda Pharmaceutical Co are an important indicator of the financial health of the company and can help investors decide whether they want to invest in the company or not.

How can one learn more about the earnings of Takeda Pharmaceutical Co?

You can learn more about the earnings of Takeda Pharmaceutical Co by reviewing the quarterly or annual reports or following the company presentations.

How much dividend does Takeda Pharmaceutical Co pay?

Over the past 12 months, Takeda Pharmaceutical Co paid a dividend of 192 JPY . This corresponds to a dividend yield of about 4.64 %. For the coming 12 months, Takeda Pharmaceutical Co is expected to pay a dividend of 185.23 JPY.

What is the dividend yield of Takeda Pharmaceutical Co?

The current dividend yield of Takeda Pharmaceutical Co is 4.64 %.

When does Takeda Pharmaceutical Co pay dividends?

Takeda Pharmaceutical Co pays a quarterly dividend. This is distributed in the months of October, April, October, April.

How secure is the dividend of Takeda Pharmaceutical Co?

Takeda Pharmaceutical Co paid dividends every year for the past 23 years.

What is the dividend of Takeda Pharmaceutical Co?

For the upcoming 12 months, dividends amounting to 185.23 JPY are expected. This corresponds to a dividend yield of 4.48 %.

In which sector is Takeda Pharmaceutical Co located?

Takeda Pharmaceutical Co is assigned to the 'Health' sector.

Wann musste ich die Aktien von Takeda Pharmaceutical Co kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Takeda Pharmaceutical Co from 12/1/2024 amounting to 98 JPY, you needed to have the stock in your portfolio before the ex-date on 9/27/2024.

When did Takeda Pharmaceutical Co pay the last dividend?

The last dividend was paid out on 12/1/2024.

What was the dividend of Takeda Pharmaceutical Co in the year 2023?

In the year 2023, Takeda Pharmaceutical Co distributed 184 JPY as dividends.

In which currency does Takeda Pharmaceutical Co pay out the dividend?

The dividends of Takeda Pharmaceutical Co are distributed in JPY.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

The Takeda Pharmaceutical Co stock can be added to a savings plan with the following providers: Consorsbank

Andere Kennzahlen von Takeda Pharmaceutical Co

Our stock analysis for Takeda Pharmaceutical Co Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Takeda Pharmaceutical Co Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.